Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

112.50 -1.41 (-1.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 374,640
Open 113.67
Bid (Size) 44.90 (200)
Ask (Size) 134.00 (100)
Prev. Close 113.91
Today's Range 109.36 - 115.57
52wk Range 18.23 - 151.18
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+12.2%
+12.2%
1 Month
+41.3%
+41.3%
3 Month
+12.8%
+12.8%
6 Month
+93.2%
+93.2%
1 Year
+310.1%
+310.1%

More News

Read More
News headline image
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Pricing of Upsized Public Offering
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Proposed Public Offering
From Palvella Therapeutics Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
From Palvella Therapeutics Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗
Via Chartmill
Topics Earnings
News headline image
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 11, 2025 ↗
Via Benzinga
News headline image
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
What is the current price of Palvella Therapeutics, Inc. - Common Stock?
The current price of Palvella Therapeutics, Inc. - Common Stock is 112.50
When was Palvella Therapeutics, Inc. - Common Stock last traded?
The last trade of Palvella Therapeutics, Inc. - Common Stock was at 03/20/26 04:00 PM ET
What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 11.13B
How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
Palvella Therapeutics, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.